Cargando…

Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma

BACKGROUND: Cancer vaccines are designed to promote systemic antitumor immunity and tumor eradication. Cancer vaccination may be more efficacious in combination with additional interventions that may build on or amplify their effects. METHODS: Based on our previous clinical and in vitro studies, we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Butterfield, Lisa H., Vujanovic, Lazar, Santos, Patricia M., Maurer, Deena M., Gambotto, Andrea, Lohr, Joel, Li, Chunlei, Waldman, Jacob, Chandran, Uma, Lin, Yan, Lin, Huang, Tawbi, Hussein A., Tarhini, Ahmad A., Kirkwood, John M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6480917/ https://www.ncbi.nlm.nih.gov/pubmed/31014399 http://dx.doi.org/10.1186/s40425-019-0552-x

Ejemplares similares

CD8+ T cell responses in metastatic melanoma patients receiving an adenovirally antigen engineered dendritic cell vaccine +/- IFN-α
por: Du, Samuel, et al.
Publicado: (2015)

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
por: Tarhini, Ahmad A., et al.
Publicado: (2014)

Impact of checkpoint blockade on cancer vaccine–activated CD8(+) T cell responses
por: Santos, Patricia M., et al.
Publicado: (2020)

CD56(dim) CD16(−) Natural Killer Cell Profiling in Melanoma Patients Receiving a Cancer Vaccine and Interferon-α
por: Vujanovic, Lazar, et al.
Publicado: (2019)

Cellular immunity induced by a recombinant adenovirus- human dendritic cell vaccine for melanoma
por: Naveh, Hadas Prag, et al.
Publicado: (2013)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma
por: Storkus, Walter J, et al.
Publicado: (2021)

Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015)

Dendritic Cell-Based Vaccines Positively Impact Natural Killer and Regulatory T Cells in Hepatocellular Carcinoma Patients
por: Bray, Sarah M., et al.
Publicado: (2011)

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
por: Tarhini, Ahmad, et al.
Publicado: (2018)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma
por: Lowe, Devin B, et al.
Publicado: (2014)

Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours
por: Tawbi, H A, et al.
Publicado: (2011)

Targeted therapy in melanoma
por: Tawbi, Hussein, et al.
Publicado: (2009)

Alpha fetoprotein directly induces a unique pro-inflammatory, IL-2 hyperresponsive phenotype in human natural killer cells
por: Vujanovic, Lazar, et al.
Publicado: (2014)

Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10
por: Vujanovic, Lazar, et al.
Publicado: (2012)

Targeted Therapy and Immunotherapy Response Assessment with F-18 Fluorothymidine Positron-Emission Tomography/Magnetic Resonance Imaging in Melanoma Brain Metastasis: A Pilot Study
por: Nguyen, Nghi C., et al.
Publicado: (2018)

Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors
por: Sander, Cindy A., et al.
Publicado: (2022)

Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors
por: Kirkwood, John M., et al.
Publicado: (2012)

Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity
por: Blalock, LeeAnn T., et al.
Publicado: (2012)

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series
por: Holbrook, Kourtney, et al.
Publicado: (2019)

Impact of Interferon-alpha1b (IFN-α1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma
por: Liu, Yu, et al.
Publicado: (2020)

Comparison of morphology, phenotypes and function between cultured human IL-4-DC and IFN-DC
por: Jin, Zhiliang, et al.
Publicado: (2017)

Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab
por: Retseck, Janet, et al.
Publicado: (2016)

Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients
por: Adamik, Juraj, et al.
Publicado: (2023)

USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity
por: Hong, Bangxing, et al.
Publicado: (2014)

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma
por: Retseck, Janet, et al.
Publicado: (2018)

Interleukin 32 expression in human melanoma
por: Paz, Helicia, et al.
Publicado: (2019)

The Regulation of Immune Responses by DC Derived Type I IFN
por: Ng, Dennis, et al.
Publicado: (2013)

The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition
por: Kreidieh, Firas Y., et al.
Publicado: (2023)

Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab
por: Najjar, Yana G., et al.
Publicado: (2017)

Tumor-derived alpha fetoprotein directly impacts human natural killer cell activity and viability
por: Vujanovic, Lazar, et al.
Publicado: (2015)

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015)

Implications of post-translational modifications of IRF7 on pDC IFN-alpha response
por: Griesbeck, M, et al.
Publicado: (2012)

Transduction of human dendritic cells with adenovirus encoding anti-PD-1 reduces PD-1 expression on co-cultured T cells
por: Patricia, Santos, et al.
Publicado: (2014)

Antitumor immunity induced by VE-cadherin modified DC vaccine
por: Zhou, Jing, et al.
Publicado: (2017)

Essential DC/DC Converters
por: Luo, Fang Lin
Publicado: (2005)

Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy
por: Lau, Eric, et al.
Publicado: (2015)

Advanced DC/DC converters
por: Luo, Fang Lin, et al.
Publicado: (2017)

Advanced DC/DC converters
por: Luo, Fang Lin, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8c74cars1je4p8pin622qmll37